Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm

Cholic acid-based therapy for Autoimmune diabetes: Tauroursodeoxycholic Acid (TUDCA) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 30/January/2019, 9.27 am
February 18, 2019
Molecular therapy for Diabetes Mellitus: Canagliflozin(trade name Invokana or Sulisent), a sodium-glucose cotransporter-2 inhibitor used in the treatment of TIIDM, augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 18/February/2019, 1.00 pm
February 18, 2019
Show all

Introduction: What they say:

A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge, Massachusetts, USA shows that “Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.” This study was published, in the 5 July 2017 issue of the journal “Nature” [One of the best journals in General Science with an I.F of 43 plus], by Prof. and the co-founder of Broad Institute Schreiber SL, Viswanathan VS and others, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene


From Significance of the study to Public health relevance: 

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally; (ii) cancer deaths globally are expected to be doubled in the next decade; (iii) metastasis is the principle reason for most of the cancer deaths; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (v) activate patients’ immune system against tumors (Cancer immunotherapy); (vi) anti-cancer drugs that target cancer stem cells that aid in tumor relapse and resistance; (vii) anti-cancer drugs that target cell adhesion molecules that aid in metastatic spread; (viii) a cheaper alternative to the existing expensive anticancer drugs; (ix) a side-effect-free natural product-based drug; (x) increase the therapeutic index of anti-cancer drugs; and (xi) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


What we infer from what they say:

A number of studies suggest that transition from one cell state to another promotes drug resistance to multiple classes of cancer therapies. The resistance to anti-cancer drug therapy limits their effectiveness. Furthermore, it has been reported that high mesenchymal cell state, which promotes resistance to anti-cancer drug therapy, is observed in a number of human cancers. However, the mechanistic basis of the therapy-resistant mesenchymal state is far from understood.

Prof.Schreiber’s research team has recently shown that:(1) a lipid-peroxidase pathway, that is responsible for the prevention of ferroptosis (a non-apoptotic form of cell death), is activated in a number of cancer cells; (2) phospholipid glutathione peroxidase (GPX4), that is responsible for dissipation of lipid peroxides that promote ferroptic cell death, is activated in epithelial-derived carcinomas, (TGFß-mediated therapy-resistance) melanoma, prostate cancer, and sarcomas; (3) tumors that depend on glutathione peroxidase (GPX4) are characterized by high expression of epithelial to mesenchymal transition (EMT) protein Zeb1; (4) inhibition of the lipid peroxidase pathway has made therapy-resistant cancer cells vulnerable to ferroptosis, suggesting that dismantling GPX4-signaling network in cancer cells characterized by therapy-resistant mesenchymal state, will make them sensitive to anti-cancer drug therapy.


From research findings to therapeutic opportunity :

This study suggests a natural product-derived therapy for drug-resistant prostate cancer metastasis.  Simvastatin and Navitoclax (ABT263) (SAN) have been shown to function as anticancer agents (fig. 1). However, the detailed mechanistic insights are yet to emerge.

A therapeutic mix encompassing Simvastatin and Navitoclax (ABT263) (SAN), by increasing the expression of its target genes, it may decrease the expression of upstream and downstream components of glutathione-dependent antioxidant enzyme GPX4 (fig. 1). Thereby, it may: (i) inhibit lipid-peroxidase pathway; (2) accumulate lipid peroxides; (3) increase ferroptosis; (4) suppress mesenchymal state in therapy-resistant cancers; (5) decrease the expression of EMT protein Zeb1; (6) increase the expression of a number of tumor suppressor genes;(iv) dismantle GPX4 signaling network; (7) inhibit tumor growth; (8) reduce metastasis; and (9) promote survival (Fig 2).

Figure 1. Mechanistic insights into how a therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) suppresses the expression of GPX4 to make therapy-resistant mesenchymal state sensitive to anti-cancer drug therapy

Figure 2. The chemical structure of Simvastatin and Navitoclax (ABT-263) (SAN)

Thus, pharmacological formulations encompassing “Simvastatin and Navitoclax (ABT263) (SAN) or their analogs, either alone or in combination with other known anticancer drugs” may be used to inhibit therapy-resistant mesenchymal state-enriched human cancers.

[easy_payment currency=”USD”]


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How does a therapeutic mix encompassing Simvastatin and Navitoclax (ABT263) (SAN) decrease the expression of GPX4 to augment sensitivity of therapy-resistant cancer cells to anticancer therapy?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, kindly drop us a line at admin@genomediscovery.org

Comments are closed.